Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : Boun Kim TanMathieu ChalouniDominique Salmon CeronAlexandre CinaudLaure EsterleMarc Arthur LokoChristine KatlamaIsabelle Poizot-MartinDidier NeauJulie ChasPhilippe MorlatEric RosenthalKarine LacombeAlissa NaqviKarl BarangeOlivier BouchaudAnne GervaisCaroline Lascoux-CombeDaniel GaripuyLaurent AlricCécile GoujardPatrick MiailhesHugues AumaitreClaudine DuvivierAnne SimonJose-Luis Lopez-ZaragozaDavid ZucmanFrançois RaffiEstibaliz LazaroDavid ReyLionel PirothFrançois BouéCamille GilbertFirouzé Bani-SadrFrançois DabisPhilippe SogniLinda WittkopFranck Boccara
• Organismes : Hôpital Cochin [AP-HP] Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Team MORPH3EUS Université de Bordeaux Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Université Paris Descartes - Paris 5 Hôtel-Dieu Team MORPH3EUS Université de Bordeaux Team MORPH3EUS Université de Bordeaux CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Sainte-Marguerite [CHU - APHM] Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Hôpital Pellegrin Université de Bordeaux CHU Tenon [AP-HP] Team MORPH3EUS Université de Bordeaux Hôpital Saint-André [Bordeaux] Hôpital l'Archet Université de Nice Sophia-Antipolis Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Hôpital l'Archet Centre Hospitalier Universitaire de Toulouse Hôpital Avicenne [AP-HP] Université Sorbonne Paris Nord AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Pharmacochimie et Biologie pour le Développement Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Hôpital de la Croix-Rousse [CHU - HCL] Centre Hospitalier Saint Jean de Perpignan Imagine - Institut des maladies génétiques (IHU) CHU Pitié-Salpêtrière [AP-HP] Hôpital Henri Mondor Hôpital Foch [Suresnes] Centre d’Investigation Clinique de Nantes Hôpital Pellegrin Hôpital Haut-Lévêque [CHU Bordeaux] Le Trait d'Union, centre de soins de l'infection par le VIH [CHU Strasbourg] CHU Dijon Université de Bourgogne Université Paris-Saclay AP-HP - Hôpital Antoine Béclère [Clamart] Team MORPH3EUS Hôpital universitaire Robert Debré [Reims] Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320 Team MORPH3EUS Université Paris Descartes - Paris 5 Hôpital Cochin [AP-HP] Immunité Innée - Innate Immunity Team MORPH3EUS Centre Hospitalier Universitaire de Bordeaux CHU Saint-Antoine [AP-HP] Université Sorbonne Paris Cité Pathologies biliaires, fibrose et cancer du foie [CRSA]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events. Methods: HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events. Secondary outcomes were coronary and/or cerebral ASCVD events, and peripheral artery disease (PAD) ASCVD events. Incidences were estimated using the Aalen-Johansen method. Factors associated with ASCVD were identified using cause-specific Cox proportional hazards models. Results: At baseline, median age of the study population (N = 1213) was 45.4 (interquartile range [IQR] 42.1-49.0) years and 70.3% were men. After a median follow-up of 5.1 (IQR 3.9-7.0) years, the incidence was 6.98 (95% confidence interval [CI], 5.19-9.38) per 1000 person-years for total ASCVD events, 4.01 (2.78-6.00) for coronary and/or cerebral events, and 3.17 (2.05-4.92) for PAD ASCVD events. Aging (hazard ratio [HR] 1.06; 95% CI, 1.01-1.12), prior CVD (HR 8.48; 95% CI, 3.14-22.91), high total cholesterol (HR 1.43; 95% CI, 1.11-1.83), high-density lipoprotein cholesterol (HR 0.22; 95% CI, 0.08-0.63), statin use (HR 3.31; 95% CI, 1.31-8.38), and high alcohol intake (HR 3.18; 95% CI, 1.35-7.52) were independently associated with total ASCVD events, whereas undetectable baseline viral load (HR 0.41, 95% CI, 0.18-0.96) was associated with coronary and/or cerebral events. Conclusions: HIV-HCV coinfected patients experienced a high incidence of ASCVD events. Some traditional cardiovascular risk factors were the main determinants of ASCVD. Controlling cholesterol abnormalities and maintaining undetectable HIV RNA are essential to control cardiovascular risk.

---

Fichiers liés : ciaa1014.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/09/2021
• Auteurs : Hervé JavelotCéline StraczekGuillaume MeyerClara Gitahy Falcao FariaLuisa WeinerDominique DrapierEric FakraPhilippe FossatiSébastien WeibelSophie DizetBastien LangréeM MassonR GaillardMarion LeboyerPierre-Michel LlorcaCoraline HingrayEmmanuel HaffenAntoine Yrondi
• Organismes : Laboratoire de pharmacologie et toxicologie neurocardiovasculaire Institut Mondor de Recherche Biomédicale Centre Hospitalier Universitaire [Strasbourg] Universidade Federal do Rio de Janeiro [Brasil] = Federal University of Rio de Janeiro [Brazil] = Université fédérale de Rio de Janeiro [Brésil] Centre Hospitalier Universitaire [Strasbourg] Laboratoire de Psychologie des Cognitions Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes] Centre Hospitalier Guillaume Régnier [Rennes] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Institut du Cerveau = Paris Brain Institute Hôpitaux Universitaires de Strasbourg Centre Hospitalier Chalon-sur-Saône William Morey Centre Hospitalier Guillaume Régnier [Rennes] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Conseil national des universités CHU Clermont-Ferrand Université Clermont Auvergne Centre d'Investigation Clinique de Besançon Université de Franche-Comté Toulouse NeuroImaging Center
• Publié dans L'Encéphale le 30/10/2020

---

Résumé : The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information.

---

Fichiers liés : Javelot et al-2021-Psychotropics and COVID-19.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/09/2021
• Auteurs : Dérioz PierreLaurent ArcusetPhilippe BachimonYves HascoëtMaud LoireauPhilippe Béringuier
• Organismes : UMR 228 Espace-Dev, Espace pour le développement Université d'Avignon Université d'Avignon UMR 228 Espace-Dev, Espace pour le développement Institut de Recherche pour le Développement (IRD en Occitanie) Université de Perpignan Via Domitia Géographie de l'environnement

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Amine BenadjiXavier DuvalKostas DanisBruno HoenBernard PageGuillaume BéraudVéronique Vernet-GarnierChristophe StradyNathalie BrieuLaurence MaulinCarine RoyMarie-Cécile PloyJacques GaillatEmmanuelle VaronSarah TubianaXavier DuvalBruno HoenBruno MourvillierMarie-Cécile PloySarah TubianaEmmanuelle VaronFrançois CaronPierre-Edouard BollaertOlivier GaillotMuhamed-Kheir TahaClaire PoyartStephane BonacorsiFrançois VandeneschEmmanuelle CambauMarc LecuitAlain GravetBruno FrachetThomas DebrouckerDaniel Levy BruhlFrançois RaffiMarie PreauNadia AnguelLaurent ArgaudSophie AristaLaurence Armand-LefevreStéphanie BalavoineRégine BaraducGuilène BarnaudGuillaume BeraudLouis BernardGeorges BernarsDominique BerteiEmilie BessedeTyphaine Billard-PomarèsCharlotte BironStéphane BlandJulien BoileauPatrice BoubeauSandra BourdonAurore BousquetSophie BoyerAlexis Bozorg-GrayeliLaurent BretCédric BretonniereFrançois BricaireElsa BrocasMichel BrunJennifer BuretChristophe BurucoaJean CabalionMathieu CabonEmmanuelle CambauGuillaume CamusetChristophe CanevetFrançois CaronAnne CarricajoBernard CastanEric CaumesCharles CazanaveAmélie ChabrolThibaut Challan-BelvalVanessa Chanteperdrix-MarillierChantal ChaplainCaroline Charlier-WoertherHélène ChaussadeCatherine ChirouzeBernard ClairJulien ColotJean-Marie ConilHugues CordelPhilippe CormierJoël CoussonPierrick CronierEric CuaAnne Dao-DubremetzSylvie DargereNicolas DegandSophie DekeyserDeborah DelauneEric DenesPierre-Francois DequinDiane DescampsElodie DesclouxJean-Luc DesmaretzJean-Luc DiehlJérôme DimetAurélien DinhXavier DuvalLelia EscautClaude FabeFrédéric FaibisClara FlateauNathalie FonsaleEmmanuel ForestierNicolas FortineauAmandine Gagneux-BrunonCaroline GarandeauMagali GarciaDenis GarotStéphane GaudryFrançois GoehringerAlain GravetValérie Gregoire-FaucherMarine GrossetCamélia GubavuIsabelle GueitDominique GuelonThomas GuimardJérôme GuinardTahar HadouJean-Pierre HeleneSandrine HenardBenoit HenryAnne-Cécile HochartBruno HoenGabriela IllesSylvain JaffuelIrène JarrinFrançoise JaureguyCédric JosephMarie-Emmanuelle JuvinSamer KayalSolen KernéisIsabelle LamauryPhilippe LanotteEtienne LaurensHenri LaurichesseCécile Le BrunVincent Le MoingPaul Le TurnierHervé LecuyerSylvie LedruCéline LegrixAdrien LemaignenChantal LembleLudovic LemeeOlivier LesensMarion LevastClaire LhommetSilvija MalesEdith MalpoteGuillaume Martin-BlondelMatthieu MarxRaphael MassonOlivier MatrayAurore MbadiFrédéric MechaiGuillaume MellonAudrey MerensMarie Caroline MeyohasAdrien MichonJoy Mootien YoganadenDavid MorquinStéphane MoulyNatacha MrozekSophie NguyenYohan NguyenMaja OgielskaEric OziolBernard PageSolène Patrat-DelonIsabelle PatryAndré PechinotSandrine PicotDenys PierrejeanLionel PirothClaire PlassartPatrice PlessisMarie-Cécile PloyLaurent PortelPatrice PoubeauMarie PoupardClaire PoyartThierry PrazuckLuc QuaesaetFrançois RaffiAdriatsiferana RamanantsoaChristophe RappLaurent RaskineJosette RaymondMatthieu RevestAgnès RicheStéphanie Robaday-VoisinFrédéric RobinJean-Pierre RomaszkoFlorence RousseauAnne-Laure RouxCécile RoyerMatthieu SaadaDominique SalmonCarlo SaroufimJean-Luc SchmitManuela SebireChristine SegondsValérie Sivadon-TardyNathalie SoismierOlivia SonSimon SunderFlorence SuyDidier TandeJacques TankovicNadia ValinNicolas van GrunderbeeckFrançois VandeneschEmmanuelle VaronRenaud VerdonMichel VergnaudVéronique Vernet-GarnierMagali VidalVirginie VitratDaniel VittecoqFanny VuottoIsabelle GorenneCédric LaouenanEstelle MarcaultFrance MentreBlandine PasquetCarine RoySarah TubianaPhilippe ArsacMartha BenoitLouis BernardFrançois BissuelLaurent BretNatalie BrieuJennifer BurretClaudia CarvalhoschneiderHélène ChampagneJoséphine ChapalainHubert ChardonPascal ChavanetJudith DucruetOlivier EpaulardMarc FabreDominique FasquelleEmmanuel ForestierJean-Marc GalempoixGuillaume GautierClaire Goulard de CurraizeAlain GracetCamélia GubavuJerome GuinardTarik HabetAurélie HaudourCaroline HenryCécile HombrouckaletCéline JanssenJean-Paul KistemanPhilippe LanotteMarie-Frédérique LartigueClaire LaunoisCécile LebrunLaurence LegoutMarion LevastYannick MadouxLaurence MaulinStéphanie MestralletAbdo MoharebJoy MootienYohan NguyenFranck NoelMaja OgielskaAgathe Ogier DesserreyAnne PaleauSimona PavelAndré PechinotIsabelle PellouxCamille PetillonHélène PetitprezBianca PodacJerome PoirotBénédicte PonceauNathalie PrieurChristine ReculeOrlando SaraceniJacques SartreFarid SifaouiCatherine SimoninChristophe StradyCharlotte TelliniAnthony TexierMaxime ThouveninAnne TixierPauline TremeauxPascale VergerVéronique Vernet-GarnierJean-Pierre VerquinVirginie VitratIsabelle VrayOana ZamfirLaure Zucchini
• Organismes : Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique Infection, Anti-microbiens, Modélisation, Evolution Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique Services de Maladies Infectieuses et Tropicales [CHU Bichat] Santé publique France - French National Public Health Agency [Saint-Maurice, France] Service des Maladies Infectieuses et Tropicales [CHRU Nancy] Centre de recherche en épidémiologie et santé des populations Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 Polyclinique Saint André Centre Hospitalier du Pays d'Aix CH du Pays d'Aix, Aix-en-Provence AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université de Limoges Service des Maladies Infectieuses Hôpital Européen Georges Pompidou [APHP] CHI Créteil Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat] Infection, Anti-microbiens, Modélisation, Evolution Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique Services de Maladies Infectieuses et Tropicales [CHU Bichat] Service des Maladies Infectieuses et Tropicales [CHRU Nancy] Hôpital universitaire Robert Debré [Reims] Université de Reims Champagne-Ardenne Université de Limoges Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat]
• Publié dans Infection le 27/10/2020

---

Résumé : Purpose: Invasive pneumococcal disease (IPD) is responsible for substantial mortality and morbidity worldwide. We aimed to identify host and bacterial factors associated with 30-day mortality in 18-year-old patients hospitalized with IPD in France from 2013 to 2015.Methods: This study analyzed data collected from consecutives IPD cases included in two parallel multi-center cohort studies: COMBAT study (280 patients with pneumococcal community-acquired bacterial meningitis) and SIIP study (491 patients with non-meningitis IPD). Factors associated with 30-day mortality were identified using logistic regression.Results: Among the 771 enrolled patients (median age 66 years, IQR [52.0-79.7]), 592/767 (77.2%) had at least one chronic disease. Patients with meningitis were younger (60.2 vs 70.9 years; p < 0.001) and had fewer chronic diseases than those with non-meningitis IPD (73.3% vs 79.4%; p = 0.05). Non-vaccine serotypes were more frequent in meningitis patients than in those with other IPD (36.1% vs 23.1%; p < 0.001). The overall 30-day mortality was 16.7% and patients with concurrent meningitis and extra-cerebral IPD had the highest 30-day mortality rate (26.5%). On multivariate analyses, older age, history of malignant solid tumor, meningeal IPD and serotypes previously identified with high mortality potential were independently associated with 30-day mortality. Of the serotypes with high mortality potential, 80% were included in licensed (PCV13 or PPV23) vaccines.Conclusion: We observed an effect of both host factors and pneumococcal serotypes on 30-day mortality in IPD. This highlights the need for a focused strategy to vaccinate at-risk patients.Clinical trial: ClinicalTrial. Gov identification number: NCT01730690.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Joanna KedraRaphaele SerorPhilippe DieudéArnaud ConstantinEric ToussirotElias KfouryCharles MassonDivi Yk CornecJean Jacques DubostLaurent MarguerieSebastien OttavianiFranck GradosRakiba BelkhirOlivier FainPhilippe GoupilleChristelle SordetBruno FautrelPeggy PhilippeMuriel PipernoBernard CombeOlivier LambotteChristophe RichezJérémie SellamThomas SenéGuillaume DenisThierry LequerreThierry LazureXavier MarietteGaetane Nocturne
• Organismes : Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre de Physiopathologie Toulouse Purpan Centre de Rhumatologie [CHU Toulouse] Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier de Brive-la-Gaillarde Centre Hospitalier Universitaire d'Angers CHRU Brest - Service de Rhumatologie CHU Clermont-Ferrand Institut Calot [Fondation Hopale] AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Amiens-Picardie Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU Saint-Antoine [AP-HP] CHU Trousseau [APHP] Centre Hospitalier Universitaire [Strasbourg] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Lyon Sud [CHU - HCL] Centre Hospitalier Régional Universitaire [Montpellier] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU de Bordeaux Pellegrin [Bordeaux] Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier de Rochefort Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes CHU Rouen Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
• Publié dans RMD Open : Rheumatic & Musculoskeletal Diseases le 21/10/2020

---

Résumé : Objectives To study the characteristics of B-cell non-Hodgkin’s lymphoma (NHL) or Hodgkin lymphoma complicating rheumatoid arthritis (RA) and to identify RA-related factors associated with their occurrence. Methods A multicentre case–control study was performed in France. Cases were patients with RA fulfilling ACR-EULAR 2010 criteria in whom B-cell NHL or Hodgkin lymphoma developed after the diagnosis of RA. For each case, 2 controls were assigned at random from the ESPOIR cohort and were matched on age at lymphoma diagnosis (cases)/age at the 10-year follow-up visit in the cohort (controls). Case and control characteristics were compared to identify parameters associated with the occurrence of lymphoma. Results 54 cases were included and matched to 108 controls. Lymphomas were mostly diffuse large B-cell lymphoma (DLBCL, n=27, 50.0%). On immunochemistry, 4 of 27 (14.8%) lymphoma cases were positive for Epstein-Barr virus. On univariate analysis, factors associated with the occurrence of lymphoma were male sex (OR 3.3, 95% CI 1.7 to 6.7), positivity for ACPA (OR 5.1, 95% CI 2.0 to 15.7) and rheumatoid factor (OR 3.9, 95% CI 1.6 to 12.2), and erosions on radiographs (OR 3.8, 95% CI 1.7 to 8.3) and DAS28 (OR 2.0, 95% CI 1.5 to 2.7), both at the time of matching. Methotrexate, TNF blockers and a number of previous biologics were not associated with the occurrence of lymphoma. On multivariable analysis, erosions and DAS28 remained significantly associated with increased risk of lymphoma. Conclusion Lymphomas complicating RA are mostly DLBCL. Risk of lymphoma in patients with RA was increased with markers of disease activity and severity, which supports the paradigm of a continuum between autoimmunity and lymphomagenesis in RA.

---

Fichiers liés : e001698.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Sophie MartinCharlotte KaeufferPierre LeyendeckerNicolas TuzinYoussef TaziFrédérique Schaff-WendlingTiffanie KleinhenyStéphanie Husson-WetzelGuillaume PamartJean-Marc LimacherOlivier ClercElise DicopJean-Emmanuel KurtzPhilippe BarthélémyJustine Gantzer
• Organismes : Institut de Cancérologie de Strasbourg Europe Hôpitaux Universitaires de Strasbourg Service de radiologie [Strasbourg] Laboratoire d'Épidémiologie et de Santé Publique [Strasbourg] Clinique Sainte Anne [Strasbourg] Clinique de l'Orangerie [Strasbourg] Groupe hospitalier de la région de Mulhouse et Sud-Alsace Groupe hospitalier de la région de Mulhouse et Sud-Alsace Service de chirurgie thoracique [Strasbourg] Hôpital Louis Pasteur [Colmar] Maison de Santé Béthel [Oberhausbergen] Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe
• Publié dans Oncologist le 26/10/2020

---

Résumé : Abstract We describe a large series of patients with solid tumors in an early COVID-19 cluster in the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 patients with cancer under treatment or on follow-up for any type of malignant solid tumor and positive for SARS-CoV-2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified as a subset of more vulnerable patients; immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic. Implications for Practice This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. This study identified patients with gastrointestinal cancers as a more vulnerable subset of patients with cancer and found that immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis to be risk factors for death. The reported data indicate the necessity of weighing the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies in any future wave of COVID-19.

---

Source

---

• Type de publi. :
• Date de publi. : 01/09/2021
• Auteurs : Daria Kartasheva-EbertzJesintha GastonPierre-Philippe MassaultOlivier ScattonSebastien GaujouxJean-Christophe VaillantStanislas PolSylvie Lagaye
• Organismes : Immunobiologie des Cellules dendritiques Université Paris Cité Hôpital Cochin [AP-HP] Université Paris Cité CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Service d'hépatologie médicale [CHU Cochin] Université Paris Cité Immunobiologie des Cellules dendritiques

---

Résumé : Il‐17A is considered to guide liver inflammation and fibrosis. Using human liver slice culture, we aim to study whether IL‐17A is capable of influencing the fibrogenesis, but also, to look into lymphatic immune cell composition, secreting IL‐17A. Using human liver samples (F0‐F4) and blood samples, collected after partial hepatectomy due to different pathologies, we analyzed IL‐17A secretion and immune cell profile. Liver tissue was used for primary culture of human liver slices, followed by subsequent cytokine stimulation and analysis by Elisa of fibrotic markers. The Huh7.5.1 cell line was used for SeaHorse and WB analysis. IL‐17A concentration in human liver tissue was significantly higher in the early fibrotic stage compared with the advanced stage. Th17 T cells and, to a lesser extent, MAIT cells are the main sources of IL‐17A in both compartments, liver and blood. Moreover, the presence of liver Th17IL‐ 17A+INFγ+ cells were detected. IL‐17A stimulation of human liver slices increases the expression of profibrotic markers. Stimulation by IL‐17A+TGF‐β1 removes the reserve respiratory capacity in Huh7.5.1 cells, while RA addition is capable to restore it and to reverse the expression of LC3II/LC3I ratio. IL‐17A, secreted by Th17 and MAIT cells, induce the expression of pro‐fibrotic markers. However, the level of hepatic IL‐17A secretion is probably more related to the underlying pathologies that cause fibrosis rather than to the mechanism of fibrosis itself. There is also a terrain of communication between IL‐17A and retinoic acid in the liver, that should be investigated.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Stéphanie LejeuneRony SfeirVéronique RousseauArnaud BonnardThomas GelasMadeleine AumarNicoleta PanaitPierre-Yves RabattuSabine IrtanVirginie FouquetAurélie Le MandatStephan de Napoli CocciEdouard HabonimanaThierry LamireauJean-Louis LemelleFrédéric ElbazIsabelle TalonNadia BoudaoudHossein AllalPhilippe BuissonThierry PetitEmmanuel SapinHubert LardyFrançoise SchmittGuillaume LevardAurélien ScalabreJean-Luc MichelOlivier JabyCécile PelatanPhiline de VriesCorinne BorderonLaurent FourcadeJean BreaudMyriam ArnouldCécilia TolgYann ChaussyStephan GeissChristophe LaplaceElodie DrumezSawsan El MouradCaroline ThumerelleFrédéric Gottrand
• Organismes : Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Centre de référence des affections congénitales et malformatives de l'oesophage Hôpital Necker - Enfants Malades [AP-HP] AP-HP Hôpital universitaire Robert-Debré [Paris] Hospices Civils de Lyon Institute for Translational Research in Inflammation - U 1286 Centre de référence des affections congénitales et malformatives de l'oesophage CHU Marseille Service de chirurgie pédiatrique [CHU Grenoble] CHU Trousseau [APHP] Centre de Recherche Saint-Antoine Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Bordeaux population health Centre Hospitalier Régional Universitaire de Nancy CHU Rouen Biomatériaux et Bioingénierie Hôpitaux Universitaires de Strasbourg Hôpital universitaire Robert Debré [Reims] Département Chirurgie Pédiatrique [CHRU Montpellier] CHU Amiens-Picardie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire d'Angers Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service de Chirurgie pédiatrique [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne Centre Hospitalier Universitaire de La Réunion Centre Hospitalier Intercommunal de Créteil Centre Hospitalier Le Mans (CH Le Mans) Centre Hospitalier Régional Universitaire de Brest CHU Clermont-Ferrand Hôpital Dupuytren [CHU Limoges] Centre Hospitalier Universitaire de Nice Centre Hospitalier Regional d'Orléans Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Centre Hospitalier Régional Universitaire de Besançon Hôpitaux Civils de Colmar CHU Pointe-à-Pitre / Abymes [Guadeloupe] Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Service de Biostatistiques [CHRU Lille] Institute for Translational Research in Inflammation - U 1286 Groupe Hospitalier Artois-Ternois Centre Hospitalier d’Arras Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286
• Publié dans Pediatrics le 02/11/2020

---

Résumé : BACKGROUND AND OBJECTIVES Respiratory diseases are common in children with esophageal atresia (EA), leading to increased morbidity and mortality in the first year. The primary study objective was to identify the factors associated with readmissions for respiratory causes in the first year in EA children. METHODS A population-based study. We included all children born between 2008 and 2016 with available data and analyzed factors at birth and 1 year follow-up. Factors with a P value <.10 in univariate analyses were retained in logistic regression models. RESULTS Among 1460 patients born with EA, 97 (7%) were deceased before the age of 1 year, and follow-up data were available for 1287 patients, who constituted our study population. EAs were Ladd classification type III or IV in 89%, preterm birth was observed in 38%, and associated malformations were observed in 52%. Collectively, 61% were readmitted after initial discharge in the first year, 31% for a respiratory cause. Among these, respiratory infections occurred in 64%, and 35% received a respiratory treatment. In logistic regression models, factors associated with readmission for a respiratory cause were recurrence of tracheoesophageal fistula, aortopexy, antireflux surgery, and tube feeding; factors associated with respiratory treatment were male sex and laryngeal cleft. CONCLUSIONS Respiratory morbidity in the first year after EA repair is frequent, accounting for >50% of readmissions. Identifying high risk groups of EA patients (ie, those with chronic aspiration, anomalies of the respiratory tract, and need for tube feeding) may guide follow-up strategies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Bruno FrançoisHasan JafriJean ChastreMiguel Sánchez-GarcíaPhilippe EggimannPierre-François DequinVincent HuberlantLucia Viña SoriaThierry BoulainCédric BretonnièreJérôme PuginJosep TrenadoAna Catalina Hernandez PadillaOmar AliKathryn ShoemakerPin RenFrank CoenjaertsAlexey RuzinOlivier BarraudLeen TimbermontChristine LammensVadryn PierreYuling WuJulie VignaudSusan ColbertTerramika BellamyMark EsserFilip DubovskyMarc BontenHerman GoossensPierre-François LaterreDidier ChochradAlain DiveFrédéric ForetMarc SimonHerbert SpapenJacques CreteurYves BouckaertPatrick BistonMarc BourgeoisMartin NovacekTomas VymazalPetr SvobodaJan PachlVladimir SramekMichal HanauerTomas HrubyMartin BalikTomas SuchyAlain LepapeLaurent ArgaudFrédéric DaillerArnaud DesachyChristophe GuittonAlain MercatFerhat MezianiJean-Christophe NavellouRene RobertBertrand SouweineJean-Marc TadieAdel MaamarDjillali AnnaneFabienne TamionAntoine GrosSaad NseirCarole SchwebelGilles FranconyJean-Yves LefrantFrancis SchneiderMatthias GründlingJohann MotschLorenz ReillCaroline RolfesTobias WelteOliver CornelyFrank BloosMaria DejaKatrin SchmidtFrank WapplerAndreas Meier-HellmannApostolos KomnosVasileios BekosVasilios KoulourasIoanna SoultatiGeorgios BaltopoulosGeorgios FilntisisEpaminondas ZakynthinosSpyros ZakynthinosIoannis PnevmatikosIldikó KrémerZoltán SzentkeresztyAgnes SarkanyZsuzsa MarjanekPedro MouraMaria Consuelo Pintado DelgadoJuan Carlos Montejo GonzálezPaula RamirezAntonio Torres MartiJuan Carlos ValiaJose LorenteAna Loza VazquezRaúl de Pablo SanchezDolores EscuderoRicard Ferrer RocaJean-Luc PaganiMarco Maggiorini
• Organismes : Centre d'Investigation Clinique de Limoges Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques Service de Réanimation Polyvalente [CHU Limoges] AstraZeneca CHU Pitié-Salpêtrière [AP-HP] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Centre d’Investigation Clinique [Tours] CIC 1415 Centre d’Etude des Pathologies Respiratoires [Tours] Hospital Universitario Central de Asturias Centre Hospitalier Regional d'Orléans Hôpital Guillaume-et-René-Laennec [Saint-Herblain] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Hospital Universitario Mutua de Terrassa Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques CHU Limoges AstraZeneca AstraZeneca AstraZeneca University Medical Center [Utrecht] AstraZeneca Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques CHU Limoges Antwerp University Hospital [Edegem] Antwerp University Hospital [Edegem] AstraZeneca AstraZeneca CHU Limoges Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques AstraZeneca AstraZeneca AstraZeneca AstraZeneca Centre d'Investigation Clinique de Limoges Antwerp University Hospital [Edegem] Université Catholique de Louvain = Catholic University of Louvain
• Publié dans The Lancet Infectious Diseases le 29/10/2020

---

Résumé : Background Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. Methods We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland. Eligible patients were in the ICU, aged ≥18 years, were intubated and on mechanical ventilation, were positive for S aureus colonisation of the lower respiratory tract, as assessed by quantitative PCR (qPCR) analysis of endotracheal aspirate, and had not been diagnosed with new-onset pneumonia. Patients were excluded if they had confirmed or suspected acute ongoing staphylococcal disease; had received antibiotics for S aureus infection for more than 48 h within 72 h of randomisation; had a Clinical Pulmonary Infection Score of 6 or higher; had an acute physiology and chronic health evaluation II score of 25 or higher with a Glasgow coma scale (GCS) score of more than 5, or an acute physiology and chronic health evaluation II score of at least 30 with a GCS score of 5 or less; had a Sequential Organ Failure Assessment score of 9 or higher; or had active pulmonary disease that would impair the ability to diagnose pneumonia. Colonised patients were randomly assigned (1:1:1), by use of an interactive voice or web response system, to receive either a single intravenous infusion of suvratoxumab 2000 mg, suvratoxumab 5000 mg, or placebo. Randomisation was done in blocks of size four, stratified by country and by whether patients had received systemic antibiotics for S aureus infection. Patients, investigators, and study staff involved in the treatment or clinical evaluation of patients were masked to patient assignment. The primary efficacy endpoint was the incidence of S aureus pneumonia at 30 days, as determined by a masked independent endpoint adjudication committee, in all patients who received their assigned treatment (modified intention-to-treat [ITT] population). Primary safety endpoints were the incidence of treatment-emergent adverse events at 30 days, 90 days, and 190 days after treatment, and the incidence of treatment-emergent serious adverse events, adverse events of special interest, and new-onset chronic disease at 190 days after treatment. All primary safety endpoints were assessed in the modified ITT population. This trial is registered with ClinicalTrials.gov (NCT02296320) and the EudraCT database (2014-001097-34).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Gustave MabiamaDieudonné AdiogoPierre-Marie PreuxJean-Claude DesportPhilippe FayemendyPierre Jésus
• Organismes : Neuroépidémiologie Tropicale Epidémiologie des Maladies Chroniques en zone tropicale Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges]
• Publié dans Clinical Nutrition ESPEN le 24/10/2020

---

Résumé : Background and aims: Although the ageing of the Cameroonian population is a public health issue in the coming years, the nutritional status of the elderly is unknown. The aim of the study was to assess the nutritional status, health status and associated socio-demographic factors among elderly in Cameroon.Methods: A cross-sectional study of 599 elderly (aged 60) was conducted in urban and rural areas. Several socio-demographic, sanitary, and anthropometric (weight, height, body mass index (BMI), Waist Circumference (WC), Mid-Upper Arm Circumference (MUAC)) data were collected. Nutritional status was defined according to WHO. Multinomial analysis was performed to identify factors associated with nutritional status. The threshold of statistical significance was 5%.Results: The population, representative of the elderly, was aged 68.9 ± 7.2 years, with sex ratio M/F ¼ 0.93, weight 68.5 ± 14.7 kg, BMI 24.7 ± 5.3,WC 90.1 ± 12.8 cm and MUAC 28.2 ± 5.0 cm. According to BMI, undernutrition was 19.7%, normal status 37.9%, overweight 24.9%, obesity 17.5%. The concordance for undernutrition between BMI and MUAC was weak (kappa ¼ 0.3). In multinomial analysis, only no medication was negatively associated with undernutrition (OR ¼ 0.3). Obesity was positively associated with the urban environment (OR ¼ 4.8) and inactivity (OR ¼ 2.9) and negatively associated with male gender (OR ¼ 0.4), widowed (OR ¼ 0.2), head of household (OR ¼ 0.4), no income (OR ¼ 0.3), one pathology(OR ¼ 0.4), no medication (OR ¼ 0.2), having normal diastolic pressure (OR ¼ 0.2).Conclusions: Undernutrition and obesity (more frequent in women, and in urban area) affect 37.2% of the elderly. These nutritional disorders are a public health problem that cannot be ignored.

---

Fichiers liés : S2405457721003090.pdf

---

Source